Cuorips Inc. (4894.T)
JPY 4585.0
(-4.18%)
JPY 4585.0
(-4.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -518 Million JPY | -39.04% |
| 2022 | -371.78 Million JPY | -32.78% |
| 2021 | -280.4 Million JPY | -26.78% |
| 2020 | -221.16 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -177.51 Million JPY | -36.93% |
| 2023 FY | - JPY | -39.04% |
| 2023 Q4 | -128.49 Million JPY | 23.52% |
| 2023 Q3 | -168.01 Million JPY | -7.4% |
| 2023 Q1 | -134.82 Million JPY | -43.15% |
| 2023 Q2 | -156.43 Million JPY | -16.02% |
| 2022 FY | - JPY | -32.78% |
| 2022 Q4 | -94.18 Million JPY | 0.0% |
| 2021 FY | - JPY | -26.78% |
| 2020 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 154.065% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -6.119% |
| GNI Group Ltd. | 14.48 Billion JPY | 103.575% |
| Linical Co., Ltd. | 1.24 Billion JPY | 141.532% |
| Trans Genic Inc. | 240.95 Million JPY | 314.981% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 61.795% |
| Soiken Holdings Inc. | -583.2 Million JPY | 11.181% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 14.109% |
| AnGes, Inc. | -8.86 Billion JPY | 94.153% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 59.704% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 92.999% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 504.349% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 39.977% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 52.555% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1065.499% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 33.212% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -363.323% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 57.251% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 62.486% |
| PeptiDream Inc. | 7.37 Billion JPY | 107.023% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 73.156% |
| Ribomic Inc. | -1.01 Billion JPY | 48.841% |
| SanBio Company Limited | -4.52 Billion JPY | 88.552% |
| Healios K.K. | -3 Billion JPY | 82.774% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 55.566% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 62.816% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 63.053% |
| StemRIM | -2.03 Billion JPY | 74.508% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 139.65% |
| FunPep Company Limited | -952 Million JPY | 45.588% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 41.717% |
| Stella Pharma Corporation | -723.85 Million JPY | 28.439% |
| TMS Co., Ltd. | -937 Million JPY | 44.717% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 33.195% |
| K Pharma,Inc. | 366.05 Million JPY | 241.508% |
| Takara Bio Inc. | 8.02 Billion JPY | 106.456% |
| ReproCELL Incorporated | 8.24 Million JPY | 6382.596% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 689.051% |
| StemCell Institute Inc. | 534.35 Million JPY | 196.939% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 311.589% |
| CellSeed Inc. | -836.51 Million JPY | 38.076% |